CRL vs NTLA · rev $2.00B vs rev $22.7M
Charles River Laboratories (CRL) versus Intellia Therapeutics Inc (NTLA) — a side-by-side from cached financials, not a winner call.
Charles River Laboratories (CRL) is a diagnostics & research company listed on US.
Intellia Therapeutics Inc (NTLA) is a biotechnology company listed on US.
Latest reported CRL revenue for 2026-06-27 was $2.00B. Net income was -$16.3M. CRL currently screens at market cap $7.78B.
Latest reported NTLA revenue for 2026-06-30 was $22.7M. Net income was -$202.9M. Revenue was up 50.9% from 2026-03-31 to 2026-06-30. NTLA currently screens at market cap $1.19B.
CRL currently screens at market cap $7.78B. NTLA currently screens at market cap $1.19B.
Not investment advice. Open the CRL and NTLA stock pages for the full models.
Not investment advice.